PEPVAC

PEPVAC predicts peptides that bind multiple human leukocyte antigen (HLA) class I supertypes to enable selection of promiscuous epitopes for multi-epitope vaccine development.

Key Features:

• Promiscuous binder prediction: Predicts peptides capable of binding multiple HLA molecules that share peptide-binding specificities (supertypes).
• HLA class I supertypes targeted: Focuses on five HLA class I supertypes: A2, A3, B7, A24, and B15.
• Population coverage: Targets supertypes that collectively cover an estimated 95% of phenotypic population frequency across various ethnicities.
• Conserved MHC ligand identification: Identifies conserved MHC ligands to prioritize broadly relevant epitopes.
• Proteasomal cleavage consideration: Identifies peptides with a C-terminus resulting from proteasomal cleavage to refine epitope selection.
• Epitope candidate reduction: Narrows down the number of potential epitopes while maintaining extensive population coverage.

Scientific Applications:

• Multi-epitope vaccine design: Facilitates selection of promiscuous HLA class I ligands for inclusion in multi-epitope vaccines.
• Broad-population targeting: Supports design strategies aimed at achieving broad phenotypic coverage across diverse ethnicities.
• Epitope refinement: Enables prioritization of conserved ligands and peptides with proteasomal cleavage-compatible C-termini for more realistic epitope candidates.

Methodology:

Targets the HLA class I supertypes A2, A3, B7, A24, and B15 to predict promiscuous peptide binders and to identify conserved MHC ligands and peptides whose C-terminus results from proteasomal cleavage.